$ODTX

Odyssey Therapeutics, Inc.

Odyssey Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. It develops medicines for people with autoimmune and inflammatory diseases. Its drug development work focuses on therapies intended to address these conditions and the needs of patients affected by them.

AlphAI earnings readThird Quarter 2026 · NOV 4Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $ODTX in the last 7 days.

No SEC Form 4 filings for $ODTX in the last 30 days.

See all $ODTX insider activity →

Odyssey Therapeutics Reports Q3 2026 Net Loss of $53.1 Million

Odyssey Therapeutics reported a Q3 2026 net loss of $53.1M, up from $35.5M a year earlier. The company has $387M in cash, expecting to fund operations into 2H 2028. R&D expenses rose to $42.1M. Clinical trials for OD-001, OD-002, and OD-004 are progressing, with key data expected in 2027. The company appointed new executives.

Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-

ODTX sentiment & insider activity

Recent ODTX coverage spans financial news and earnings.

What's driving ODTX

AlphAI scores every news story that mentions ODTX with an AI model for sentiment and relevance, and aggregates insider trades from Odyssey Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ODTX

Score

Odyssey Therapeutics Reports Q3 2026 Net Loss of $53.1 Million

Odyssey Therapeutics reported a Q3 2026 net loss of $53.1M, up from $35.5M a year earlier. The company has $387M in cash, expecting to fund operations into 2H 2028. R&D expenses rose to $42.1M. Clinical trials for OD-001, OD-002, and OD-004 are progressing, with key data expected in 2027. The company appointed new executives.

$ODTXHighAI 8/10Earnings

Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-

Odyssey Therapeutics: Phase 2a OD-001 shows significant mMS improvement, 20 mg BID selected for Phase 2b

Odyssey Therapeutics reported positive Phase 2a results for OD-001, meeting its primary endpoint with a 2.4-point mean modified Mayo score reduction. The 20 mg BID dose showed 27% clinical remission and 61% clinical response. Biomarkers indicated reduced inflammation, and the treatment was well-tolerated. The company plans to advance to Phase 2b with this dose.

Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More

Wall Street analysts issued updates on multiple companies. Biogen (BIIB) was upgraded to Overweight with a $300 target, First Solar (FSLR) to Buy with a $270 target, and Salesforce (CRM) to Buy with a $285 target. Adobe (ADBE) was downgraded to Underweight with a $225 target, and Snowflake (SNOW) to Accumulate with a $515 target. Robinhood (HOOD) was initiated with an Outperform rating and $130 target.

Odyssey Therapeutics to present phase 2a trial design for UC

Odyssey Therapeutics (NASDAQ:ODTX) will present a Phase 2a trial design for OD-001 combined with vedolizumab in ulcerative colitis at the American College of Gastroenterology 2026 Annual Scientific Meeting. The trial will enroll up to 146 patients globally, with topline results expected in the second half of 2027. The company aims to target both innate and adaptive immunity in the disease.

Raymond James initiates Odyssey Therapeutics stock coverage with outperform rating

Raymond James initiated coverage on Odyssey Therapeutics (ODTX) with an Outperform rating and a $42.00 price target. The stock is currently at $18.12, down 11% in the past week but up 10% year-to-date. The company is developing treatments for autoimmune and inflammatory conditions, with its lead asset OD-001 in Phase 2 trials. Analysts highlight the company's long-term potential and preclinical pipeline, though cash burn is noted.

Related tickers